Warning Cookies are used on this site to provide the best user experience. If you continue, we assume that you agree to receive cookies from this site. OK

M.D. Jan Hynek

In the first phase of our clinical study we evaluated the results after giving the preparation to patients. Patient's consent was essential in line with adequate information provision regarding the advantages and disadvantages of the product administration.


Penoxal 50 mg was given 3x1 for 3 months, usually repeatedly with a pause of 3 months. We checked HB, HT, thrombocytes, leucocytes and differential counts, liver tests, HD/ LD cholesterol, urea, blood glucose, s- amylase and BP.

In our study, 45 patients were assigned to 5 groups:

Female patients with a higher risk of breast cancer - 7 patients

Patients with a dysplastic nevus syndrome (FAMMM) - 15 patients

Polyps and other risk factors in patients with a high risk of colon Ca - 3 patients

Patients with severe family medical history - 7 patients

Patients with a confirmed tumour (3 with breast Ca, 3 with melanoma Clark I, 4 with melanoma Clark III, 1 with
melanoma Clark IV, 4 with confirmed colon tumour), out of these cases, one was inoperable.

Present evaluation:

  • Product tolerance is excellent; apart from 2 cases, most patients experienced changes to their stools and they felt as if their bowels were completely emptied, this feeling intensified after drinking milk.
  • Biochemistry was collected repeatedly. 1x we found a decreased LD cholesterol level. No signs of changes.
  • CBC showed no changes including leucocytes and a differential count.

M.D. Jan Hynek
Centre for Clinical Oncology and Mammology
Palackého ul.201, Trutnov